On March 7, 2022, the company announced an increase in its equity buyback plan. The company increased its authority by $5 million, thereby bringing the total authorization to $15 million.
La Jolla Pharmaceutical Company
Equities
LJPC
US5034596040
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
-1.17% | 102B | |
+2.87% | 96.09B | |
+2.13% | 22.28B | |
-14.77% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.21% | 16.09B | |
+8.55% | 13.83B | |
+35.75% | 11.97B |